• Hafiz Muhammad Nadeem, Asghar Ali, Nighat Shahbaz, Tariq Ghafoor, Tariq Azam Khattak, and Qamar Un Nisa Chaudary.
• Department of Clinical Haematology, Armed Forces Institute of Bone Marrow Transplant Centre, Rawalpindi, Pakistan.
• J Coll Physicians Surg Pak. 2024 Mar 1; 34 (3): 355359355-359.

ObjectiveTo compare donor graft characteristics and clinical outcomes in recipients of allogeneic heamatopoietic stem cell transplantation (HSCT) using GCSF primed bone marrow (GBM) and steady-state bone marrow (SBM) as stem cell sources.Study DesignObservational study. Place and Duration of the Study: Department of Clinical Haematology, Armed Forces Bone Marrow Transplant Centre, Rawalpindi, Pakistan, from August 2018 to October 2020.MethodologyEighty patients undergoing allogeneic HSCT were analysed. Among these, forty each received GBM and SBM from HLA identical siblings. Graft characteristics, such as total nucleated cells, CD34+ cell yield; clinical outcomes such as neutrophil and platelet engraftment, primary and secondary graft failure (GF), as well as the frequency of acute and chronic graft versus host disease (GvHD), were recorded and compared using the t-test, with significance at p <0.05.ResultsA statistically significant difference was observed in CD34+ dose with median dose 7.68 (p=0.002) but not in TNC dose with meadin dose 5 (p=0.86). Neutrophil engraftment occurred much more quickly with median of 13.43 days in the GBM than SBM group (p=0.025). While no statistically significant difference (p=0.89) in platelet engraftment was reported in both SBM and GBM. At the same time, patients with both GBM and SBM transplants showed a comparable ratio of acute to chronic GvHD and primary to secondary GF.ConclusionGBM is associated with better CD34+ stem cell yield and quicker neutrophil engraftment in clinical outcomes.Key WordsGranulocyte colony-stimulating factor, Bone marrow, Hematopoietic stem cell transplantation.

6 keywords...

hide…